#1 Clinical Trials Search in Europe

Human Normal Immunoglobulin (Iv)

Human Normal Immunoglobulin (IV), also known as intravenous immunoglobulin (IVIG), is being studied in various clinical trials for its potential therapeutic benefits across different medical conditions. This article explores the ongoing research into the use of IVIG in treating disorders such as immune thrombocytopenia, primary antibody deficiencies, and other immune-related conditions. We’ll examine the objectives, patient criteria, and potential outcomes of these trials to better understand how IVIG might improve patient care in the future.

Table of Contents

What is Human Normal Immunoglobulin (IV)?

Human Normal Immunoglobulin (IV), also known as IVIG (Intravenous Immunoglobulin) or Human Normal Immunoglobulin for Intravenous Administration, is a medication derived from human blood plasma[1]. It contains antibodies that help the body’s immune system fight infections and regulate immune responses.

How Does It Work?

Human Normal Immunoglobulin (IV) works by providing the body with additional antibodies. These antibodies can help:

  • Fight infections in people with weakened immune systems
  • Reduce inflammation in autoimmune disorders
  • Modulate the immune system in certain conditions

Medical Conditions Treated

Human Normal Immunoglobulin (IV) is used to treat various medical conditions, including:

  • Primary Antibody Deficiencies: Such as Common Variable Immunodeficiency (CVID), agammaglobulinemia, and specific antibody deficiencies[2]
  • Immune Thrombocytopenia (ITP): A condition where the immune system mistakenly attacks platelets[3]
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): A rare condition affecting fetuses and newborns[4]
  • Langerhans Cell Histiocytosis: A rare disorder involving an excess of immune cells called Langerhans cells[5]
  • Anti-NMDA Receptor Encephalitis: An autoimmune condition affecting the brain[6]
  • Hypophosphatasia: A rare inherited disorder affecting bone and tooth development[1]

How Is It Administered?

As the name suggests, Human Normal Immunoglobulin (IV) is administered intravenously, meaning it is given directly into a vein. This is typically done in a hospital or clinical setting under medical supervision. The infusion can take several hours, depending on the dose and the patient’s tolerance[2].

Dosage Information

The dosage of Human Normal Immunoglobulin (IV) varies depending on the specific condition being treated, the patient’s weight, and their response to treatment. Some general dosage ranges include:

  • For primary antibody deficiencies: 400-800 mg/kg every 3-4 weeks[2]
  • For immune thrombocytopenia: 1-2 g/kg over 2-5 days[3]
  • For fetal and neonatal alloimmune thrombocytopenia: Up to 1 g/kg per week during pregnancy[4]
It’s important to note that dosages should always be determined and adjusted by a healthcare professional.

Potential Side Effects

While Human Normal Immunoglobulin (IV) is generally well-tolerated, some potential side effects may occur:

  • Headache
  • Fever or chills
  • Nausea or vomiting
  • Fatigue
  • Muscle pain
  • Allergic reactions (rare)
Serious side effects are rare but can include kidney problems, blood clots, or aseptic meningitis. Patients should report any unusual symptoms to their healthcare provider immediately[3].

Ongoing Research and Clinical Trials

Several clinical trials are currently investigating the use of Human Normal Immunoglobulin (IV) in various conditions:

  • A study on its effectiveness in preventing lung disease progression in patients with primary antibody deficiency[2]
  • Research on its use in combination with other treatments for immune thrombocytopenia[3]
  • Investigation of its potential in treating anti-NMDA receptor encephalitis[6]
These ongoing studies aim to optimize treatment protocols and explore new applications for this versatile medication.

Condition Trial Objective Key Inclusion Criteria Primary Endpoint
Immune Thrombocytopenia (ITP) Compare IVIG + prednisone vs. dexamethasone for ITP with bleeding Adults with ITP, platelet count ≤20×10^9/L, bleeding manifestations Time to achieve initial response within 5 days
Primary Antibody Deficiency (PAD) Evaluate higher IVIG dosing on lung disease progression PAD diagnosis, indication for IVIG therapy Difference in lung disease scores over 2 years
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Compare IVIG to nipocalimab in pregnancies at risk of FNAIT Pregnant women with anti-HPA-1a/5b antibodies, fetal HPA-1a/5b genotype Adverse outcome of death or severe bleeding in utero/neonatal period
Langerhans Cell Histiocytosis (LCH) Evaluate treatment strategies for LCH in children and adolescents Histologically verified LCH diagnosis, no prior systemic therapy Reactivation-free survival, overall survival
Anti-NMDA Receptor Encephalitis Assess inebilizumab vs. placebo (with standard care including IVIG) Anti-NMDAR encephalitis diagnosis, mRS score ≥3 Change in mRS score at 16 weeks

FAQ

  • What is Human Normal Immunoglobulin (IV)? Human Normal Immunoglobulin (IV), also called IVIG, is a blood product made from the plasma of many donors. It contains antibodies that help fight infections and regulate the immune system.
  • What conditions are being studied with IVIG in clinical trials? Clinical trials are exploring IVIG for conditions such as immune thrombocytopenia, primary antibody deficiencies, fetal and neonatal alloimmune thrombocytopenia, and Langerhans Cell Histiocytosis, among others.
  • How is IVIG administered in these trials? IVIG is typically given through an intravenous infusion. The dosage and frequency can vary depending on the specific condition being treated and the trial protocol.
  • Are there any side effects associated with IVIG treatment? While IVIG is generally well-tolerated, some potential side effects may include headache, fever, chills, and allergic reactions. The trials closely monitor patients for any adverse events.
  • How long do these clinical trials typically last? The duration of clinical trials for IVIG can vary widely, ranging from a few weeks to several months or even years, depending on the specific study objectives and the condition being investigated.

Ongoing Clinical Trials on Human Normal Immunoglobulin (Iv)

  • A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Czechia Denmark Estonia France +13

  • Study of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Poland Spain

  • Study on the Effectiveness and Safety of Human Normal Immunoglobulin (IV) for Adults with Chronic Immune Thrombocytopenia

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Italy Romania Spain

  • Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Nipocalimab or IVIG for Pregnant Women at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany The Netherlands Poland

  • Study on Early Immunotherapy with Human Normal Immunoglobulin, Cyclophosphamide, and Methylprednisolone for Patients with Anti-Hu Paraneoplastic Sensory Neuropathy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects and Safety of Inebilizumab for Patients with Anti-NMDA Receptor Encephalitis

    Recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Spain

  • Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Denmark Germany Sweden

  • Study on Methylprednisolone and Human Normal Immunoglobulin for Treating Fulminant Myocarditis in Patients

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Immune thrombocytopenia (ITP): A blood disorder characterized by a decreased number of platelets, which can lead to easy bruising and bleeding.
  • Primary antibody deficiency (PAD): A group of disorders where the immune system fails to produce enough antibodies, leading to increased susceptibility to infections.
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): A condition where a pregnant woman's immune system attacks her fetus's platelets, potentially causing severe bleeding in the fetus or newborn.
  • Langerhans Cell Histiocytosis (LCH): A rare disorder involving an excess of immune cells called Langerhans cells, which can accumulate in various organs and cause damage.
  • Intravenous Immunoglobulin (IVIG): A blood product made from pooled plasma donors, containing antibodies used to treat various immune-related conditions.
  • Hypophosphatasia: A rare inherited disorder that affects bone and tooth development due to low levels of an enzyme called alkaline phosphatase.
  • Anti-NMDA receptor encephalitis: An autoimmune disorder where the body's immune system attacks NMDA receptors in the brain, leading to neurological symptoms.
  • Bronchiectasis: A chronic lung condition where the airways become abnormally widened, leading to mucus buildup and increased risk of infections.
  • Immunosuppressive therapy: Treatment that reduces the activity of the immune system, often used to prevent rejection of transplanted organs or to treat autoimmune diseases.
  • Alloantibody: An antibody produced by the immune system in response to antigens from another individual of the same species.

References

  1. http://clinicaltrials.eu/trial/study-on-immunosuppressive-therapies-with-asfotase-alfa-for-patients-with-hypophosphatasia-experiencing-reduced-treatment-effectiveness/
  2. http://clinicaltrials.eu/trial/study-on-the-effect-of-human-normal-immunoglobulin-on-lung-disease-in-patients-with-primary-antibody-deficiency/
  3. http://clinicaltrials.eu/trial/study-on-dexamethasone-prednisolone-and-immunoglobulin-for-adults-with-immune-thrombocytopenia-and-moderate-to-severe-bleeding/
  4. http://clinicaltrials.eu/trial/study-of-nipocalimab-or-ivig-for-pregnant-women-at-risk-of-fetal-and-neonatal-alloimmune-thrombocytopenia-fnait/
  5. http://clinicaltrials.eu/trial/study-on-langerhans-cell-histiocytosis-treatment-in-children-and-adolescents-using-cladribine-prednisolone-and-cytarabine/
  6. http://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-inebilizumab-for-patients-with-anti-nmda-receptor-encephalitis/